Final results from PARAMOUNT, a Phase III study of ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Eli+Lilly+%28LLY%29+Further+ALIMTA+Phase+III+PARAMOUNT+Data+Shows+Positive+Effects+on+Curbing+Nonsquamous+NSCLC+Progression/6811049.html for the full story.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.